| Heading: |
Restless Legs Syndrome: Medical Treatments |
| Question ID: |
1816554 |
| UIN: |
62829 |
| House: |
Commons |
| Date tabled: |
2025-06-25 |
| Asking Member ID: |
5191 |
| Asking Member display name: |
Adam Dance
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Adam Dance
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the potential risks of dopamine agonists as a treatment for restless leg syndrome. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
NHS England has made no assessment. The Medicines and Healthcare products Regulatory Agency (MHRA) assesses all medicines before they are licensed in the United Kingdom, with regard to quality, safety, and efficacy. The licensed dopamine agonist medicines... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |